Technical Data Sheet

InVivoMAb anti-mouse NKG2A/C/E

Attention: Use of this product constitutes an agreement to Bio X Cell's Terms and Conditions which are included with this product in print and can also be found at https://bioxcell.com/terms-and-conditions.

Lot Specific Information

Lot Number: **Lot Specific***
Volume: **Lot Specific***
Concentration: **Lot Specific* (generally 4 to 11 mg/ml) ***
Total Protein: **Lot Specific***

*This information will be noted on the certificate of analysis that ships with this product.

Product Information

Catalog Number:	**BE0321**
Clone:	**20D5**
Isotype:	Rat IgG2a, κ
Recommended Isotype Control(s):	InVivoMAb rat IgG2a isotype control, anti-trinitrophenol
Recommended Dilution Buffer:	InVivoPure pH 7.0 Dilution Buffer
Immunogen:	CHO transfected cells expressing the C57BL/6 allele of NKG2A and CD94
Reported Applications:	*in vivo* NKG2A blockade (see description) *in vitro* NKG2A blockade Immunohistochemistry (frozen) Flow cytometry
Formulation:	PBS, pH 7.0 Contains no stabilizers or preservatives
Endotoxin:	≤1EU/mg (≤0.001EU/μg) Determined by LAL gel clotting assay
Purity:	≥95% Determined by SDS-PAGE
Sterility:	0.2 μm filtration
Production:	Purified from cell culture supernatant in an animal-free facility
Purification:	Protein G
RRID:	AB_2819048
Molecular Weight:	150 kDa

Description

The 20D5 monoclonal antibody reacts with mouse NKG2A, NKG2C, and NKG2E also known as CD159a, CD159c, and CD159e respectively. The NKG2 receptors belong to a family of C-type lectin-like receptors that form heterodimers with CD94. NKG2/CD94 heterodimeric complexes are primarily expressed on NK cells and NKT cells. NKG2 receptors are also expressed on CD8+ T cells activated in vivo and in vitro. NKG2/CD94 heterodimeric complexes recognize Qa-1, a nonclassical MHC class I antigen, presenting the Qdm peptide. CD94/NKG2 heterodimers on NK cells transduce signals after ligand binding. NKG2A is thought to transduce inhibitory signals, while NKG2C and NKG2E transduce stimulatory signals. Blocking NKG2A signaling has been shown to promote anti-tumor immunity in murine tumor models by enhancing the activity of both T and NK cells. For this reason, NKG2A targeting is being explored as a novel immune checkpoint inhibitory therapy for treating human cancers. *An engineered recombinant mouse variant of the rat IgG2a anti-mouse NKG2A/C/E (clone 20D5) antibody with mouse IgG constant domains has been shown to block NKG2A signals in vivo in murine tumor models. BE0321 is the original 20D5 clone with rat IgG constant domains.

Storage

Store at the stock concentration at 4°C . **Do not freeze.**
It is not uncommon for a floccule or precipitate to appear during storage. The floccule is typically buffer salts precipitating out

of solution or a small bit of protein aggregation. For information on how to remove floccules or precipitates see our FAQ's at https://bioxcell.com/faqs.

Protocol Information

Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.

Application References

For a complete list of references, visit https://bioxcell.com/be0321?bxcs=9k1b3a#tab_references or scan the QR code below.

Bio X Cell, LLC
https://bioxcell.com
+1-866-787-3444
customerservice@bioxcell.com

Conditions: For research use only. Not for use in diagnostic or therapeutic procedures.
Not for resale.
Bio X Cell, Bio X Cell logo, and all other trademarks are the property of Bio X Cell, LLC © 2025 Bio X Cell, LLC